Sponsored

Prescient Therapeutics (ASX:PTX) makes progress in March 2023 quarter - Kalkine Media

May 01, 2023 11:46 AM AEST | By Ankit Sethi
Follow us on Google News: https://kalkinemedia.com/resources/assets/public/images/google-news.webp

Highlights

  • Prescient has informed about progress with regard to its PTX-100 therapy and cell therapu OmniCAR
  • The Company has received "excellent" results from the clinical trial of PTX-100 therapy (T Cell Lymphoma)
  • CellPryme being evaluated by potential partners to enhance cell therapies
  • PTX was also granted the Orphan Drug Designation during the quarter for PTX-100

Prescient Therapeutics (ASX: PTX), the Australian listed entity into clinical stage oncology, has released its Activities Report for the quarter ended March 2023. Aside from progress with respect to the company’s clinical trials, the report reveals a "strong" cash balance amounting to AU$19.9 million, which was further bolstered by exercise of PTXOC options after the reporting period. PTX has also informed that during the reporting quarter it enhanced its commercial expertise with global pricing and access specialist.

The oncology company is progressing with its personalised therapies for cancer, and the Activities Report mentions that Prescient Therapeutics was able to make "solid progress" in all respects. Mentioned below are some key highlights from PTX's report.

Clinical progress

Prescient states that its targeted therapy PTX-100 -- undergoing Phase 1B trial led by Professor H. Miles Prince AM -- has been able to show encouraging activity, with clinical and regulatory momentum. During the reporting quarter, the therapy showed an “excellent safety profile", and PTX states this came with "very few" adverse events. It is pertinent to note that two of the patients experienced complete eradication of cancer.

Further, seven out of 10 patients demonstrated durations of response which were higher than standard of care. Separately, the therapy was granted the Orphan Drug Designation by the US FDA last month. This designation was broader than what was sought by the Company, which highlights the significance of developing effective therapies for patients. The team is working on the Phase 2 trial of PTX-100. An additional manufacturing campaign has also begun to support Phase 2.

Source: PTX ASX release dated 9 March 2023

Prescient has appointed Mr Ed Schoonveld -- a "global authority on pricing and health economics" -- who will guide Prescient on commercial, pricing and patient access strategies for PTX-100. Separately, the company is also actively recruiting for the Phase 1b trial of PTX-200 therapy. Also, during the reporting quarter, PTX continued with OmniCAR platform development. Prescient is focused on further optimising the platform pre-clinically and incorporating feedback including gene editing.

Prescient’s CellPryme platform is presently being assessed by numerous external parties with a view to enhancing their own cell therapy platforms. The Company states this may lead to commercial arrangements. PTX received an international trademark for the platform.

Financials

Prescient reported a cash balance of AU$19.9 million at the end of the reporting quarter. Subsequently, the Company could also bank an additional AU$3.7 million from the from exercise of PTXOC options (taking the total from these proceeds to AU$4.8 million). PTX states more than 97% of options were exercised.

 


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.

5 ASX Companies Leveraging AI to Drive Growth in 2024



Top ASX Listed Companies


We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.